



Leading the Way in ES-SCLC: Achieving 6-Year Survival and Beyond

Monday, 7 April 2025

18:00–19:50 Indonesia / Thailand / Vietnam

19:00–20:50 Hong Kong / Malaysia / Singapore / Taiwan

21:00–22:50 Australia

LIVE WEBINAR

Dear Doctor,

We are pleased to invite you to attend **Leading the Way in ES-SCLC: Achieving 6-Year Survival and Beyond** on **Monday, 7 April 2025, 19:00–20:50 HKT (UTC+8)**. This event will gather experts across Asia Pacific, aiming to discuss the current state and potential applications of atezolizumab in extensive-stage small cell lung cancer (ES-SCLC) management.

Objectives

- Highlight the latest 6-year overall survival data on atezolizumab and the implications on clinical practice
- Showcase real-world evidence on:
 - The applications of atezolizumab in the management of ES-SCLC
 - The clinical benefits of the subcutaneous formulation of atezolizumab compared with the standard intravenous administration

Please reach out to your affiliate PJP for more information. To reserve your place, **please click or scan the QR code on the right.**

We look forward to your participation!

Sincerely,

Roche APAC Lung Disease Area Network



FACULTY



MODERATOR

Dr Molly Li
Assistant Professor (Clinical)
The Chinese University of Hong Kong
Hong Kong



SPEAKER

Dr Steven Kao
Associate Professor
Chris O'Brien Lifehouse
Australia



SPEAKER

Dr Kevin Mok
Associate Consultant
Prince of Wales Hospital
Hong Kong



SPEAKER

Dr Harit Suwanrusme
Medical Oncologist
Bumrungrad
International Hospital
Thailand



PANELLIST

Dr James Chow
Associate Consultant
Queen Elizabeth Hospital
Hong Kong



PANELLIST

Dr Beng Khiong Yap
Consultant
Clinical Oncologist
Subang Jaya Medical Centre
Malaysia



PANELLIST

Dr Chao-Chi Ho
Professor
National Taiwan University
Taiwan

AGENDA

Time (UTC+8)	Topic	Faculty
19:00–19:05 (5 mins)	Opening Remarks	Dr Molly Li
19:05–19:45 (40 mins)	IMbrella A 6Y OS Sharing Breaking the 6-year Survival Barrier in ES-SCLC: Integrating Long-Term Data into Clinical Practice	Dr Steven Kao
19:45–20:00 (15 mins)	Case Sharing Long Term Response to Immunotherapy in SCLC: A Case of Sustained Survival Benefit	Dr Harit Suwanrusme
20:00–20:15 (15 mins)	Case Sharing Durable Clinical Benefit with Immunotherapy in SCLC: A Case with Prolonged Survival	Dr Kevin Mok
20:15–20:45 (30 mins)	Panel Discussion	Dr James Chow Dr Chao-Chi Ho Dr Steven Kao Dr Kevin Mok Dr Harit Suwanrusme Dr Beng Khiong Yap <i>Moderated by Dr Molly Li</i>
20:45–20:50 (5 mins)	Closing Remarks	Dr Molly Li

*Hong Kong CME Accreditation (The Hong Kong College of Pathologists/ Hong Kong College of Physicians/ Hong Kong College of Radiologists/ The College of Surgeons of Hong Kong) in progress.

[Approval code placeholder]